Lilly (Eli) (LLY)
Health Care · Pharmaceuticals
Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies.
What Lilly (Eli) does
Eli Lilly and Company is a global pharmaceutical leader that discovers, develops, and manufactures medicines for human health. The company focuses on major therapeutic areas including diabetes, obesity, immunology, neuroscience, and oncology. It leverages research and development to address complex medical conditions through both traditional pharmaceutical products and emerging biotechnological innovations.
Themes: obesity drugs, diabetes care, GLP-1 / metabolic health, oncology, immunology, neuroscience, biopharmaceuticals
Fundamentals
- Price$1,169.60 as of 2026-10-08 close
- Market cap$1.10T as of 2026-08-03 (share count; price 2026-10-08)
- 1-year return+38.3% 2025-10-08 close $845.72 → 2026-10-08 close $1,169.60
- P/E39.25 as of 2026-10-08
- Net margin+31.7% FY2025, SEC XBRL
- ROE+77.8% FY2025, SEC XBRL
- Debt / equity1.62 as of 2026-09-03
- Revenue growth (YoY)+49.6% as of 2026-09-03
- Revenue CAGR (3y)+31.7% SEC XBRL
- Beta0.55 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.6%; at least 10 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How LLY compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 10% 430 covered Health Care peers, as of 2026-09-03
- return on equitytop 10% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- indicated dividend yieldbottom 25% 72 covered Health Care peers, as of 2026-09-03
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
LLY is in the Top 10 — Health Care.
Top 10 — Health Care — since 18 Aug 2026
Top 10 score
66.2 #84 of 1,379 scored · #11 of 151 in Health Care
Profitability 97th (return on equity 77.8%) and growth 94th (revenue growth year over year 49.6%, 3-year revenue CAGR 31.7%); weakest is valuation (17th, price to book 32.5, price to earnings 39.3).
In this list since 18 Aug 2026 — currently 10th in the list (51 days)
- Entered 18 Aug 2026: first selection for this list at rank 1, score 66.0.
- Held its place at 2 rebalances between 1 Sep 2026 and 1 Oct 2026.
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, LLY's dividend was covered by reported results (earnings payout 26%, operating-cash-flow payout 32%). This describes past coverage, not a forecast.
- Earnings payout26% dividends / net income
- Operating-cash-flow payout32% dividends / operating cash flow — capital spending was not reported, so this does not subtract it
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Lilly (Eli) looks technically
Lilly (Eli) (LLY) is trading 8.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 229 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It made a new 20-day high about 2 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 8.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +8.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1173.48 | $1173.48 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1074.79 | $1074.79 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 1215. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 229 trading days ago — a "golden cross", a bullish long-term signal | 229 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend) | 20.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30) | 51.6 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($1131.21 to $1215.00) — its "stochastic" reading is 46 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 45.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $1292.65 | $1292.65 |
|---|---|---|
| From the 52-week high | it is 9.5% below its 52-week high (its highest price of the past year) | -9.5% |
| Above the 52-week low | it is 49.2% above its 52-week low (its lowest price of the past year) | +49.2% |
| Below the 52-week high | it is 9.5% below its highest point of the past year | 9.5% |
| Since a 20-day breakout | it made a new 20-day high about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 36 trading days ago | 36 sessions |
| All-time high | its highest closing price on record is $1292.65 (set on 2026-08-19) | $1292.65 |
| Given back of the 52-week move | over the past year its closes ranged ($799.57 to $1280.34), and it has given back roughly a quarter of its rise from last year’s low — 23% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $967.84 to $983.22. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 23.0% |
| From the all-time high | it is 9.5% below its all-time high | -9.5% |
| Nearest price level | it is trading 2.6% above a support level at $1139.16 — a price it turned at three times since 2026-01-08, most recently on 2026-07-15. Since 2024-10-08 it has 13 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.6% |
| All-time low | its lowest closing price on record is $27.00 (set on 1996-07-30) | $27.00 |
| Above the all-time low | it is 4231.9% above its all-time low | +4,232% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move | 2nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $34.87 between its high and its low — about 3.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $34.87 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1119.13 and $1197.14 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1119.13 – $1158.14 – $1197.14 |
| Typical daily range (% of price) | its price moves about 3.0% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.0% |
| Stretch from the 200-day average | it is trading 2.7 daily ranges above its 200-day average price (8.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.30× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.3% since the prior reading | +0.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.4% |
|---|---|---|
| Open gap | it gapped 2.4% above the previous close 18 sessions ago and has not traded back through the level it left behind at 1115.7 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.4% |
| Gap filled | a 2.7% gap up opened on 2026-09-01 has been "filled" 24 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 24 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 3.0 percentage points (the stock gained 4.1% while the market gained 1.0%) | +3.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 7.6 percentage points (the stock lost 3.8% while the market gained 3.8%) | -7.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 8.7 percentage points (the stock gained 26.2% while the market gained 17.5%) | +8.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 23.3 percentage points (the stock gained 38.3% while the market gained 15.0%) | +23.3% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.8% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 1.4% of the share price, which is taken to mean a barrier that gives way easily. | -1.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 9% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $1072.77 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +9.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $1179.06 — a volume-weighted average of daily closes over 46 sessions, not a true tick-by-tick VWAP. | -0.8% |
Head and shoulders, bearish — forming · entry $1,115.71 · 51 sessions in
Price levels it has turned at before
LLY last closed at $1169.60 on 2026-10-08. Since 2024-10-08 it has turned at 13 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1139.16 | Support | 2.6% below the last close | turned there three times · 2026-01-08 to 2026-07-15 |
| $1223.50 | Resistance | 4.6% above the last close | turned there twice · 2026-07-28 to 2026-09-30 |
| $1112.11 | Support | 4.9% below the last close | turned there four times · 2025-11-26 to 2026-09-11 |
| $1090.87 | Support | 6.7% below the last close | turned there three times · 2025-12-23 to 2026-06-18 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $1215.00.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 2 trading days, since 2026-10-07.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · in a Bollinger Band volatility squeeze · beating the market · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.63 mean, 1=Strong Buy…5=Strong Sell) — 29 analysts
- Mean price target$1,328.83 range $930.00 – $1,600.00; median $1,385.00
Analyst estimates, as of 2026-10-03. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for LLY
- Consensus EPS estimate$9.96 next reporting period, as of 2026-10-03
- Estimate change, 30 days+$0.0845 (+0.9%) from $9.87, on 2026-08-29, 35-day window
- Readings revised upward43% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on a concentrated portfolio of products and potential supply chain disruptions.","Intense pricing and reimbursement pressures from governmental and private payers.","High costs and inherent uncertainties in the pharmaceutical R&D and regulatory approval process."]
What changed in the latest 10-Q
AI-assisted comparison of LLY's 10-Q filed 2026-04-30 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Added:
- FDA approved orforglipron for treatment of obesity (newer filing, 2026-04-30)
- Phase 3 trial for orforglipron for type 2 diabetes met the primary endpoint (newer filing, 2026-04-30)
- Phase 3 trial initiated for baricitinib for type 1 diabetes (newer filing, 2026-04-30)
- Phase 3 trial initiated for eloralintide incretin add-on for obesity (newer filing, 2026-04-30)
- Phase 3 trial initiated for eloralintide for obstructive sleep apnea (OSA) (newer filing, 2026-04-30)
- Phase 3 trial initiated for eloralintide for osteoarthritis (OA) pain (newer filing, 2026-04-30)
- Phase 3 trial for retatrutide for type 2 diabetes met the primary endpoint (newer filing, 2026-04-30)
- Phase 3 trial initiated for brenipatide for major depressive disorder (newer filing, 2026-04-30)
- Phase 3 trial initiated for sofetabart mipitecan for platinum-sensitive ovarian cancer (newer filing, 2026-04-30)
- FDA granted Breakthrough Therapy designation for sofetabart mipitecan for platinum-resistant ovarian cancer (newer filing, 2026-04-30)
- In first quarter of 2026, finalized voluntary agreements with U.S. government regarding Medicaid drug prices and new medicine pricing approach (newer filing, 2026-04-30)
- Medicare GLP-1 Bridge program details: Medicare beneficiaries access to discounted obesity medicines by July 1, 2026 through December 31, 2027 (newer filing, 2026-04-30)
- In January 2026, HHS selected Trulicity and Verzenio as medicines subject to government-set prices effective in 2028 (newer filing, 2026-04-30)
- Removed:
- Tirzepatide pediatric/adolescent type 2 diabetes application submitted to FDA and EC (older filing, 2025-10-30)
- Phase 3 trial for tirzepatide for cardiovascular outcomes in type 2 diabetes met primary endpoint (older filing, 2025-10-30)
- Phase 3 trial initiated for tirzepatide for type 1 diabetes (older filing, 2025-10-30)
- Withdrew U.S. application for tirzepatide for heart failure with preserved ejection fraction (older filing, 2025-10-30)
- Insulin efsitora alfa application submitted to FDA and EC for approval (older filing, 2025-10-30)
- Phase 3 trial initiated for muvalaplin for atherosclerotic cardiovascular disease (older filing, 2025-10-30)
- Phase 3 trials for orforglipron for obesity met primary and all key secondary endpoints (older filing, 2025-10-30)
- Phase 3 trials for orforglipron for type 2 diabetes met primary and all key secondary endpoints (older filing, 2025-10-30)
- Phase 3 trial initiated for orforglipron for hypertension and overweight or obesity (older filing, 2025-10-30)
- Phase 3 trial initiated for orforglipron for osteoarthritis pain of the knee and overweight or obesity (older filing, 2025-10-30)
- Phase 3 trial initiated for orforglipron for stress urinary incontinence and overweight or obesity (older filing, 2025-10-30)
- Phase 3 trial initiated for retatrutide for chronic low back pain and overweight or obesity (older filing, 2025-10-30)
- Japan's Ministry of Health, Labour and Welfare approved mirikizumab for Crohn's disease (older filing, 2025-10-30)
- EC approved donanemab for early symptomatic Alzheimer's disease (older filing, 2025-10-30)
- FDA approved imlunestrant for ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer (older filing, 2025-10-30)
- EC approved pirtobrutinib for chronic lymphocytic leukemia (older filing, 2025-10-30)
- Phase 3 trials for pirtobrutinib for CLL or SLL met primary endpoints (older filing, 2025-10-30)
- Phase 3 trial initiated for olomorasib for resected adjuvant NSCLC (older filing, 2025-10-30)
- Phase 3 trial initiated for olomorasib for unresected adjuvant NSCLC (older filing, 2025-10-30)
- FDA granted Breakthrough Therapy designation for olomorasib for newly diagnosed metastatic KRAS G12C-mutant lung cancers (older filing, 2025-10-30)
- May 2025 executive order on most-favored-nation pricing (older filing, 2025-10-30)
- July 2025 letters from U.S. presidential administration on drug pricing objectives (older filing, 2025-10-30)
- OBBBA enacted into law in July 2025 with tax and Medicaid/ACA spending cuts (older filing, 2025-10-30)
- Reworded:
- Reference to Annual Report 10-K year changed from 2024 (older) to 2025 (newer)
- Financial results presentation changed from three and nine months ended September 30 (older) to three months ended March 31 (newer), reflecting different quarterly periods
- Net income/EPS driver description: older filing cited 'increased marketing, selling, and administrative expenses and research and development expenses' as offset; newer filing cites 'higher research and development expenses and marketing, selling, and administrative expenses' offset by 'lower acquired IPR&D charges'
- Clinical pipeline language changed from 'Phase 2 or Phase 3 clinical trials' (older) to 'in clinical trials' (newer)
- Notes:
- The two filings cover different quarters (Q3 2025 in older filing versus Q1 2026 in newer filing), which explains substantial clinical development and policy differences
- Text of newer filing appears truncated at tariffs discussion; full comparison of later sections not possible
- The clinical development pipeline changes reflect different development stages and approvals that occurred between the two filing dates rather than revisions of same information
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 3 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 3 sells ($16M) — 3 selling insiders
- Last 180 days · read to 2026-10-040 buys · 6 sells ($35M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-17. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about LLY's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 54 matched disclosures for LLY from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
7 institutional 13F filers reported holding LLY as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 7
- Reported shares held 142,761,309
- Reported value $171,232,195,597
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 6 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about LLY's institutional holders → See what each manager we track holds →
Short interest (FINRA)
LLY had 7,519,918 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
LLY had 0.80% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.41 days to cover at the same settlement.
- Reported short interest (shares) 7,519,918
- Short interest (% of shares outstanding) 0.80%
- Prior settlement (shares) 7,894,476
- Reported change -4.74%
- Days to cover (reported) 3.41
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Novo Nordisk (NVO)
- Merck & Co. (MRK)
- Pfizer (PFE)
- Sanofi (SNY)
- AstraZeneca (AZN)
- Bristol Myers Squibb (BMY)
- Amgen (AMGN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare LLY vs…
Lilly (Eli) is found in…
LLY ranks in…
LLY shows up in…
Frequently asked questions
What does Lilly (Eli) (LLY) do?
Eli Lilly and Company is a global pharmaceutical leader that discovers, develops, and manufactures medicines for human health. The company focuses on major therapeutic areas including diabetes, obesity, immunology, neuroscience, and oncology. It leverages research and development to address complex medical conditions through both traditional pharmaceutical products and emerging biotechnological innovations.
What sector is Lilly (Eli) (LLY) in?
Lilly (Eli) (LLY) is classified in the Health Care sector. Its industry is Pharmaceuticals.
Does LLY pay a dividend?
Yes — Lilly (Eli) (LLY) pays a dividend, with an indicated yield of about 0.60% and at least 10 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-09-03). Informational only — not financial advice.
Who are Lilly (Eli)'s (LLY) competitors?
Notable peers of Lilly (Eli) (LLY) include Novo Nordisk, Merck & Co., Pfizer, Sanofi and AstraZeneca. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in LLY?
Yes — we hold 54 matched STOCK Act disclosures for LLY from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Lilly (Eli) (LLY) overbought or oversold right now?
Lilly (Eli) (LLY) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 52, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LLY come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.